Newsletter 4 - April 2015


Bruno Francois discussed the start of the SAATELLITE study in his blog on the 2nd of March and I am delighted to say that the Open Call for a new asset (or assets) to join MEDI4893 in COMBACTE is now open! The process of how to fill the gap left by the termination of GSK1322322 has been a learning process for both the management board and IMI as we have worked through ensuring that this is a fair and transparent process for potential interested EFPIA partners. Read more..


18 European academic partners and 3 pharmaceutical companies launched a new project under the Innovative Medicines Initiative funded New Drugs 4 Bad Bugs program: COMBACTE-CARE. COMBACTE-CARE (Combatting Bacterial Resistance in Europe-Carbapenem-Resistance) will bring highly innovative studies related to infections caused by Carbapenem-Resistant Enterobacteriaceae (CRE). Read more..

EPI-Net: COMBACTE’S 4th Pillar

The ambitious goal of this project is to significantly contribute to the reduction of heterogeneity of current surveillance systems in Europe, articulate a comprehensive epidemiologic research strategy by establishing a network of experts from academia and industry, and address research needs to support antibacterial drug development. Read more..

Project Coordinator
Dr. Helen Steel

Academic Project Coordinator
Prof. Marc Bonten
Academic Clinical Lead
Bruno Francois MD

Deputy Project Co-ordinator
Seamus O'Brien

Please contact the PMO team with your ideas for the next newsletter.
Click here to send us your thoughts! Looking forward to hearing from you!

Unsubscribe from this newsletter.

This research project receives support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115523 | 115620 | 115737 resources of which are composed of financial contribution from the European Union Seventh Framework Programme (FP7/2007-2013) and EFPIA companies in kind contribution.

Email Marketing Powered by Mailchimp